These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37142595)

  • 1. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
    Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
    Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
    Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
    Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
    J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
    Deng J; Tian AL; Pan H; Sauvat A; Leduc M; Liu P; Zhao L; Zhang S; Chen H; Taly V; Laurent-Puig P; Senovilla L; Li Y; Kroemer G; Kepp O
    Cell Death Dis; 2021 Oct; 12(11):978. PubMed ID: 34675191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
    Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
    Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer.
    Bueno-Fortes S; Muenzner JK; Berral-Gonzalez A; Hampel C; Lindner P; Berninger A; Huebner K; Kunze P; Bäuerle T; Erlenbach-Wuensch K; Sánchez-Santos JM; Hartmann A; De Las Rivas J; Schneider-Stock R
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 9. miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
    Liu H; Yin Y; Hu Y; Feng Y; Bian Z; Yao S; Li M; You Q; Huang Z
    Pathol Res Pract; 2016 Jul; 212(7):643-9. PubMed ID: 27173050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
    Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
    J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling.
    Leonard NA; Corry SM; Reidy E; Egan H; O'Malley G; Thompson K; McDermott E; O'Neill A; Zakaria N; Egan LJ; Ritter T; Loessner D; Redmond K; Sheehan M; Canney A; Hogan AM; Hynes SO; Treacy O; Dunne PD; Ryan AE
    iScience; 2024 Sep; 27(9):110701. PubMed ID: 39310770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
    Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
    J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer.
    Qu YL; Liu XL; Zhao SY; Zhai XF
    Pathol Res Pract; 2022 Jun; 234():153895. PubMed ID: 35462225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for Therapy.
    Rotermund A; Brandt S; Staege MS; Luetzkendorf J; Mueller LP; Mueller T
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
    Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
    Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.